The preferential utilization of interleukin-1R antagonists rather than TNF-a antagonists usually used in articular rheumatism is justified by the dominance of the systemic character of the disease with frequent spikes in fever and seemed efficient. The gene discussed is TNF; the disease is rheumatic disorder.